Previous 10 | Next 10 |
PG&E (NYSE: PCG ) -29% on bankruptcy judge decision clearing way for Elliott plan. More news on: PG&E Corporation, Forescout Technologies, Inc., HEXO Corp., Stocks on the move, Read more ...
Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients – No reported drug-related serious adverse events – Achieved marked reduction in Bullous Pemphigoid Disease Ar...
NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, tod...
The following slide deck was published by Akari Therapeutics, Plc in conjunction with this Read more ...
The FDA has granted Orphan Drug Designation to Akari Therapeutics' (NASDAQ: AKTX ) nomacopan for the treatment of bullous pemphigoid (BP). More news on: Akari Therapeutics, Plc, Healthcare stocks news, Stocks on the move, Read more ...
NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, tod...
Intelsat (NYSE: I ) -11% . More news on: Intelsat S.A., T2 Biosystems, Inc., Akari Therapeutics, Plc, Stocks on the move, Read more ...
NEW YORK and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, tod...
SeaChange International (NASDAQ: SEAC ) +24% on Q2 results . More news on: SeaChange International, Inc., Ambarella, Inc., Akari Therapeutics, Plc, Stocks on the move, Read more ...
The FDA has granted orphan drug designation to Akari Therapeutics' (NASDAQ: AKTX ) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). More news on: Akari Therapeutics, Plc, Healthcare stocks news, Read more .....
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potenti...
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to ...
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC: PKBO), a clinical-stage biopharmaceutical company focused on...